A 12-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 2-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to placebo, in the treatment of moderate Crohn's disease in patients intolerant or with unsatisfactory response to immunosuppressive drugs and/or TNF-inhibitors
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Masitinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors AB Science
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2017 This trial has been suspended in Slovakia.
- 13 May 2017 This trial has been discontinued in Greece (end date: 10 Feb 2017).